Tina Sampath’s Post

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/erNMsDVi

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/eWGeWyPY

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/epbYkP28

Review of 38 trials assessing #DMT impact on #QOL in people with #MS: The complexity of QOL measurement makes it challenging to draw clear conclusions from the data. Despite some positive impacts of certain DMTs, the lack of a standardized approach to assess disease-specific QOL in MS highlights the need for better incorporation of QOL measures in future clinical trials. https://lnkd.in/gDgKnidz Perrine Janiaud Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies - FENS Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Data demonstrates improvement in cognitive function in GBA1 hashtag #Parkinson’s disease model in addition to reversal of motor function deficits https://lnkd.in/gnzP6jg2

🧠 Refining surgical and radiotherapy decision-making for meningioma patients New study found that removal of the whole meningioma tumour reduces the likelihood that it will grow back, across all molecular profiling groups, but this benefit is less likely in the most biologically aggressive, proliferative tumours. However, completely removing these tumours, including treating their attachments to the dura, or membrane that surrounds the brain and spinal cord, can prolong a patient's life. The study highlights the importance in patients' molecular profiles to make better decisions for them: https://lnkd.in/g7N8De2a News story here: https://lnkd.in/g2mNGd6f Co-corresponding authors: Drs. Farshad Nassiri & Gelareh Zadeh First author: Justin Wang Research at UHN

Excited to see how this collaboration yields new biomarkers with the following three distinct but interrelated goals: ✅ Monitor ALS disease progression and treatment efficacy across cohorts from multiple participating institutions ✅ Innovate therapeutic strategies and diagnostic tools by better understanding the metabolic landscape of motor neuron cells in ALS patients ✅ Drive precision medicine advances by subsetting patients based on their unique metabo-phenotype.

New therapies on the horizon: Targeted protein degradation in neuroscience With the first PROTAC protein degrader ARV-102 entering phase I clinical trials earlier this year to treat Parkinson's disease and progressive supranuclear palsy targeting the kinase LRRK2, it's a perfect time to welcome a mini review exploring the burgeoning advancements in TPD technologies, and it's promising applications in neuroscience research while highlighting at the same time the complexity of bringing CNS-targeted PROTACs to clinical development. https://lnkd.in/gDMgumyW

Now on-demand: Keenan Walker, PhD, discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from cognitively normal individuals who later develop dementia. He also outlines how he is using this information to discover new blood-based biomarkers and potential drug targets. Watch it here: https://bit.ly/45XMt0Q #proteomics #biomarkers #neuroscience #drugdevelopment #drugdiscovery #alzheimersresearch #alzheimers

Now on-demand: Keenan Walker, PhD, discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from cognitively normal individuals who later develop dementia. He also outlines how he is using this information to discover new blood-based biomarkers and potential drug targets. Watch it here: https://bit.ly/45XMt0Q #proteomics #biomarkers #neuroscience #drugdevelopment #drugdiscovery #alzheimersresearch #alzheimers